BioCryst could earn up to $116 million plus double-digit royalties.

BioCryst Pharmaceuticals and Shionogi & Co. entered into an exclusive license agreement to develop and commercialize BioCryst’s lead influenza neuraminidase inhibitor, peramivir, in Japan for the treatment of seasonal and potentially life-threatening human influenza.

Shionogi will pay $14 million for rights to injectable formulations of peramivir. BioCryst may also receive future clinical  event payments of up to $21 million, commercial milestones of up to $95 million, and double digit royalty payments, ranging between 10% and 20%.

Previous articleProNAi and Novosom to Enable Delivery of DNAi-based Cancer Treatments
Next articleFirst New High Blood Pressure Drug in More Than a Decade Okayed